Immediate Impact
1 from Science/Nature 28 standout
Citing Papers
Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk‐Stratification, and Management
2025 Standout
Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed/refractory AML: preclinical evaluation and phase I trial
2025 Standout
Works of Leo Sekine being referenced
Adoptive immunotherapy with double‐bright (CD56bright/CD16bright) expanded natural killer cells in patients with relapsed or refractory acute myeloid leukaemia: a proof‐of‐concept study
2021
Conventional and high‐dose daunorubicin and idarubicin in acute myeloid leukaemia remission induction treatment: a mixed treatment comparison meta‐analysis of 7258 patients
2014
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Leo Sekine | 60 | 118 | 86 | 75 | 42 | 337 | |
| J. Groh | 29 | 117 | 165 | 49 | 31 | 403 | |
| Sujoy Khan | 42 | 81 | 62 | 75 | 47 | 383 | |
| Robert L. Quigley | 46 | 47 | 151 | 7 | 35 | 352 | |
| Robyn M. Hatley | 23 | 90 | 275 | 12 | 41 | 374 | |
| Şükrü Nail Güner | 14 | 70 | 40 | 34 | 42 | 307 | |
| Takahiro Jimbo | 75 | 95 | 213 | 5 | 44 | 375 | |
| Mehdi Abedinzadeh | 16 | 120 | 87 | 6 | 34 | 370 | |
| Jorge Labrador | 155 | 19 | 40 | 10 | 31 | 354 | |
| I. Joppich | 7 | 99 | 220 | 24 | 51 | 348 | |
| Massimo Cajozzo | 8 | 155 | 142 | 11 | 45 | 394 |
All Works
Login with ORCID to disown or claim papers
Loading papers...